MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months.

Pacific Biosciences, a San Francisco Bay area company offering long-read sequencing platforms, will acquire Omniome for up to $800 million. Zai Lab and Schrödinger formed a collaboration to develop a novel oncology product targeting DNA damage.

BeiGene of Beijing has been approved to stage a $3 billion IPO on the Shanghai Star Stock Exchange. It will be the first Chinese biopharma to be listed in Shanghai, Hong Kong, and the US.

The Renaissance IPO Index has rallied 77.8% since that March 18th low; double the S&P 500’s performance in the same time-frame. That has led the ratio of IPOs to the S&P 500 to have gone nearly vertical and is now at new highs

Tianjin CanSinoBIO published positive results from a China Phase I trial of its COVID-19 vaccine in the prestigious British journal, The Lancet. In the study, the Ad5 vectored COVID-19 vaccine was immunogenic at 28 days post-vaccination.